LUNGevity: Award Program for EGFR-Positive Lung Cancer (LOI)

Research that seeks to transform the future for patients diagnosed with EGFR-positive lung cancer by changing EGFR-positive lung cancer into a chronic or curable condition. Projects must include at least one translational aim that is directly related to improvement of patient outcomes and/or leads to a clinical trial. International applicants must name a co-investigator at a U.S. institution.

Funding: up to $100K/year for 2 years.

https://www.lungevity.org/research/translational-science-research-award-programs/applying-for-lungevity-award/egfr-resisters